top
Search terms
Results 1 - 10 of 11 - ordered by :
Pages: 1 2
Ehjcvp

Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Anders Sahlén, Christoph Varenhorst, Bo Lagerqvist, Henrik Renlund, Lars Wallentin, Stefan K. James, Tomas Jernberg

Date : 01/01/2016 Item size : 280123 bytes
Ehjcvp

Vice versa, patients presenting with acute coronary syndromes (ACS) develop AF in 621% of cases, hence, through the presence of vascular disease, these patients automatically require anticoagulation ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Miklos Rohla, Thomas W. Weiss, Johann Wojta, Alexander Niessner, Kurt Huber

Date : 01/07/2015 Item size : 293945 bytes
Ehjcvp

In a meta-analysis, in this issue of the journal, Kuljit Singh and co-workers from the University of Ottawa Heart Institute in Canada report that despite rapid revascularization and treatment of ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Stefan Agewall

Date : 01/10/2015 Item size : 96385 bytes
Ehjcvp

In this issue of the journal, Serebruany and co-workers report data from a study of clinical utilization of dual antiplatelet therapy (DAPT) in patients with renal impairment following percutaneous ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Stefan Agewall

Date : 01/07/2016 Item size : 96542 bytes
Ehjcvp

The EMPA-REG outcome trial showed improved survival and less hospitalization for HF: it is changing concepts and practice.1 The new era of outcome trials follows the acute awareness of the need to ...

European Heart Journal - Cardiovascular Pharmacotherapy, Editorials, Basil S. Lewis

Date : 01/10/2016 Item size : 203582 bytes
Ehjcvp

The primary trial endpoint is the composite of death, MI, hospitalization for unstable angina, urgent percutaneous coronary intervention, and urgent coronary artery bypass grafting. Introduction ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Otto Hartman, Petri T. Kovanen, Jukka Lehtonen, Kari K. Eklund, Juha Sinisalo

Date : 08/11/2016 Item size : 295073 bytes
Ehjcvp

Furthermore, even the truth changes since we perform new studies and since people challenge the truth When I was in Medical School one professor of Medicine told the class, Damn you if you treat ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Stefan Agewall

Date : 01/04/2015 Item size : 97793 bytes
Ehjcvp

Glycoprotein IIb/IIIa receptor inhibitors (GPIs) block the final common pathway leading to platelet aggregation that occurs via the cross-linking of fibrinogen and von Willebrand factor upon exposure ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Jeffrey D. Wessler, Robert P. Giugliano

Date : 01/04/2015
Ehjcvp

Current European Society of Cardiology (ESC) guidelines highlight the benefit of dual antiplatelet therapy (DAPT) consisting of acetylic salicylic acid plus one of the P2Y12 receptor inhibitors, ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Nicolas Danchin, Maddalena Lettino, Uwe Zeymer, Petr Widimsky, Alfredo Bardaji, Jose A. Barrabes, Angel Cequier, Marc J. ...

Date : 01/07/2016
Ehjcvp

Writing and submitting a manuscript forces researchers to put their data together, analyse them appropriately, make sense of them, and discuss their implications for science and ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Thomas F. Lüscher

Date : 01/01/2015